Development of a Small‐molecule as a Cancer Drug for Management of Liver Cancer
- Summary
- One of the major glucosinolates that is present in seeds of a herbal medicine showed unmatched anti-cancer properties in liver cancer in rats. Our study involved investigation of their potential therapeutic benefits both in vitro in human normal liver and cancer cell lines. In vivo study with rats with liver cancers was studied after treatment of rats via oral administration of the compound for two years. In vitro treatments of HepG2, Clone 9 and WRL-68 cell lines with the compound were performed in a time-course study. Results showed that the small-molecule inhibited the growth of the cancer cell line but showed almost no toxicity to the normal cells. Cell cycle analysis demonstrated that the growth of treated HepG2 cells were inhibited by G0/G1 phase arrest mechanism, and DNA fragmentation confirmed the apoptotic event. The present findings clearly showed that some of the small-molecules identified can inhibit cancer cell growth by inducing G0/G1 phase arrest and subsequently apoptosis. It has protective and therapeutic benefits to the liver in vivo.
242 non-conf abstract_hkstp Page 1 of 1
- Application No.
- 06/SCI/242 Inventors: Professor HO Wing Shing John, Department of Biochemistry Miss MENG Jie Jill, Department of Biochemistry Patent Status: US Patent and PCT Pending
- Country/Region
- Hong Kong
For more information, please click Here
